Showing results (31-40 of 93) with videos related to
Sort By:
Pageof 10
Blood|June 19, 2014
The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomasNiels Murawski, Gerhard Held, Marita Ziepert, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Impact of rituximab and radiotherapy on outcome of patients with aggressive B-cell lymphoma and skeletal involvementGerhard Held, Samira Zeynalova, Niels Murawski, et al.Bone Marrow Transplantation|March 24, 2020
Alternative donors provide comparable results to matched unrelated donors in patients with acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in second complete remission: a report from the EBMT Acute Leukemia Working PartyEolia Brissot, Myriam Labopin, Domenico Russo, et al.Bone Marrow Transplantation|August 18, 2022
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trialJürgen Finke, Claudia Schmoor, Matthias Stelljes, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 7, 2016
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOPNorbert Schmitz, Samira Zeynalova, Maike Nickelsen, et al.Journal of Hematology & Oncology|September 19, 2016
Unrelated donor versus matched sibling donor in adults with acute myeloid leukemia in first relapse: an ALWP-EBMT studyAnnalisa Ruggeri, Giorgia Battipaglia, Myriam Labopin, et al.Journal of Hematology & Oncology|April 18, 2018
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMTNicole Santoro, Myriam Labopin, Federica Giannotti, et al.The Lancet. Oncology|November 22, 2012
Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1)Norbert Schmitz, Maike Nickelsen, Marita Ziepert, et al.Annals of Hematology|August 8, 2023
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysisLuca Fischer, Linmiao Jiang, Joerg Thomas Bittenbring, et al.Bone Marrow Transplantation|February 8, 2024
Graft-versus-host-disease prophylaxis with ATG or PTCY in patients with lymphoproliferative disorders undergoing reduced intensity conditioning regimen HCT from one antigen mismatched unrelated donorAnnalisa Paviglianiti, Maud Ngoya, Marta Peña, et al.Pageof 10